Prosultiamine
| Code | Size | Price |
|---|
| TAR-T20851-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Prosultiamine is commonly used for treatment of beriberi, nutritional disorders caused by lack of vitamin B1, etc.
CAS:
59-58-5
Formula:
C15H24N4O2S2
Molecular Weight:
356.5
Purity:
0.98
SMILES:
CCCSSC(CCO)=C(/C)N(Cc1cnc(C)nc1N)C=O
References
1. Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. Int J Urol. 2018 Jan;25(1):54-60. doi: 10.1111/iju.13468. Epub 2017 Oct 1. PubMed PMID: 28965354.
2. Ogawa T, Kato T, Ono M, Shimizu T. [Clinical and MRI Findings in Patients with Congenital Anosmia]. Nihon Jibiinkoka Gakkai Kaiho. 2015 Aug;118(8):1016-26. Japanese. PubMed PMID: 26548095.
3. Kira J. Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Med. 2013 Aug 15;11:183. doi: 10.1186/1741-7015-11-183. PubMed PMID: 23945332; PubMed Central PMCID: PMC3826871.
4. Nakamura T, Matsuo T, Fukuda T, Yamato S, Yamaguchi K, Kinoshita I, Matsuzaki T, Nishiura Y, Nagasato K, Narita-Masuda T, Nakamura H, Satoh K, Sasaki H, Sakai H, Kawakami A. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Med. 2013 Aug 15;11:182. doi: 10.1186/1741-7015-11-182. PubMed PMID: 23945290; PubMed Central PMCID: PMC3826868.